Basic HTML Version
© The Canadian Journal of Urology™; 18(Supplement 1); April 2011
Address correspondence to Dr. Leonard G. Gomella,
Department of Urology, Kimmel Cancer Center, Thomas
Jefferson University, 1025 Walnut Street, Suite 1112,
Philadelphia, PA 19107 USA
Pharmacology for common urologic diseases:
2011 review for the primary care physician
Xiaolong S. Liu, MD,
1
Christine Folia, PharmD,
2
Leonard G. Gomella, MD
1
1
Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
2
Agro Health Associates Inc., Burlington, Ontario, Canada
LIU XS, FOLIA C, GOMELLA LG. Pharmacology
for common urologic diseases: 2011 review for the
primary care physician. The Canadian Journal of
Urology. 2011;18(Supplement 1):24-38.
Coordination of care between the urologist and primary
care physician is critical to effective treatment of a variety
of urologic conditions. Medical therapies for benign
prostatic hyperplasia, erectile dysfunction, hypogonadism,
overactive bladder, and prostate cancer are widely available
and a basic understanding of the pathophysiology of these
disease states as well as the pharmacology of existing
treatment options are necessary to avoid complications
and maximize efficacy associated with patient outcomes.
Important regulatory decisions have beenmade concerning
the approval and lack of approval of several important
urologic medications. Major advances have been made
in the therapy of castrate resistant prostate cancer as well
as hormonal related skeletal events secondary to advanced
carcinoma of the prostate. We provide a 2011 update of
the available medications for treatment of several common
urologic diseases.
Key Words:
uropharmacology, benign prostatic
hyperplasia, erectile dysfunction, hypogonadism,
overactive bladder, prostate cancer
demonstrating clinical efficacy and safety are published
in the literature. While in past decades the use of these
medications weremore limited to the urologist’s office,
primary care physicians are now often comfortable in
providing initial evaluation and treatment of many
urologic disorders. A fundamental understanding
of the pathophysiology and pharmacology of these
conditions can lead to safe and effective management
approaches for these patients. We provide a 2011 update
onuropharmacology for the primary care physician and
will give a review of the current available medications
for the treatment of both benign andmalignant urologic
diseases noting the differences in products available in
Canada and the United States (US).
1,2
Introduction
With continued research into the pathophysiology of
urologic disease processes, advances in pharmacologic
options for the management of these conditions have
been fast growing. New medications for treatment of
benign prostatic hyperplasia (BPH), erectile dysfunction
(ED), hypogonadism, overactive bladder (OAB), and
prostate cancer are continuouslymade available as trials
24